Galenica's kidney drug meets endpoint in trial

NEWYou can now listen to Fox News articles!

Swiss healthcare company Galenica said on Monday that its kidney drug PA21 successfully met primary and secondary endpoints in a late-stage trial, paving the way for regulatory filings in the United States, Europe and Switzerland.

Results of the six-month phase III study found that maintenance doses of PA21 were superior in sustaining the phosphate-lowering effect in patients with chronic kidney disease who are on dialysis versus a PA21 inactive low dose.

The company plans to submit PA21, which it developed in collaboration with Fresenius Medical Care, for regulatory approval in the fourth-quarter of 2012.